Quest Diagnostics Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Quest Diagnostics Inc trades at $230.79 (market cap $25.48B), while T-Rex 2X Long MSTR Daily Target ETF trades at $40.57 (market cap $809.00M). The key difference: Quest Diagnostics Inc is far larger — about 31.5× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| DGX | MSTU | |
|---|---|---|
Market Cap | $25.48B | $809.00M |
Volume | 941,866 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $451.00 |
52-Week Low | $173.49 | $14.60 |
Typical Hold Time | 56 Days | 18 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
MSTU trades at $39.54, showing minimal daily movement with a 0.23% gain. The technical outlook is bearish based on moving averages, while oscillators present a neutral stance. Recent corporate actions include a 10:1 reverse stock split and a $0.29 dividend scheduled for August 2026. News coverage highlights the ETF's leveraged nature and recent volatility concerns.
The outlook remains cautious due to the bearish technical signals and leveraged ETF structure, which amplifies volatility. Investment opportunities exist for tactical traders seeking short-term momentum, but risks include daily rebalancing effects and potential value erosion during sustained market moves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →